221 related articles for article (PubMed ID: 24131622)
1. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
Karlsson E; Pérez-Tenorio G; Amin R; Bostner J; Skoog L; Fornander T; Sgroi DC; Nordenskjöld B; Hallbeck AL; Stål O
Breast Cancer Res; 2013; 15(5):R96. PubMed ID: 24131622
[TBL] [Abstract][Full Text] [Related]
2. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
[TBL] [Abstract][Full Text] [Related]
3. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
Karlsson E; Magić I; Bostner J; Dyrager C; Lysholm F; Hallbeck AL; Stål O; Lundström P
PLoS One; 2015; 10(12):e0145013. PubMed ID: 26698305
[TBL] [Abstract][Full Text] [Related]
4. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
Pérez-Tenorio G; Karlsson E; Waltersson MA; Olsson B; Holmlund B; Nordenskjöld B; Fornander T; Skoog L; Stål O
Breast Cancer Res Treat; 2011 Aug; 128(3):713-23. PubMed ID: 20953835
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer.
Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M
Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
Rutkovsky AC; Yeh ES; Guest ST; Findlay VJ; Muise-Helmericks RC; Armeson K; Ethier SP
BMC Cancer; 2019 May; 19(1):491. PubMed ID: 31122207
[TBL] [Abstract][Full Text] [Related]
7. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.
Bostner J; Karlsson E; Eding CB; Perez-Tenorio G; Franzén H; Konstantinell A; Fornander T; Nordenskjöld B; Stål O
Endocr Relat Cancer; 2015 Jun; 22(3):331-43. PubMed ID: 25972244
[TBL] [Abstract][Full Text] [Related]
8. Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.
Sridharan S; Basu A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054043
[TBL] [Abstract][Full Text] [Related]
9. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R6. PubMed ID: 24447434
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
[TBL] [Abstract][Full Text] [Related]
14. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Karlsson E; Veenstra C; Emin S; Dutta C; Pérez-Tenorio G; Nordenskjöld B; Fornander T; Stål O
Breast Cancer Res Treat; 2015 Aug; 153(1):31-40. PubMed ID: 26208487
[TBL] [Abstract][Full Text] [Related]
15. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
Bostner J; Karlsson E; Pandiyan MJ; Westman H; Skoog L; Fornander T; Nordenskjöld B; Stål O
Breast Cancer Res Treat; 2013 Jan; 137(2):397-406. PubMed ID: 23242584
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.
Lehn S; Tobin NP; Sims AH; Stål O; Jirström K; Axelson H; Landberg G
BMC Cancer; 2014 Feb; 14():119. PubMed ID: 24559095
[TBL] [Abstract][Full Text] [Related]
17. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal expression of p-AMPKa and p-S6 is strongly associated with the prognosis of gastric cancer.
Zheng Z; Zheng Y; Zhang M; Wang J; Yu G; Fang W
Tumour Biol; 2016 Apr; 37(4):4803-11. PubMed ID: 26520441
[TBL] [Abstract][Full Text] [Related]
19. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
20. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]